Vibegron, marketed as Gemtesa, has received approval in Canada for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency in adult women [1].
When did Gemtesa get approved in Canada?
Health Canada authorized Gemtesa on January 26, 2022 [1].
What is Vibegron used for?
Vibegron is prescribed to adult women experiencing symptoms of overactive bladder, specifically urge urinary incontinence, urinary urgency, and urinary frequency [1]. It works by relaxing the bladder muscle, which helps to increase bladder capacity and reduce the sudden urge to urinate [2].
How does Gemtesa compare to other OAB treatments?
Gemtesa offers an alternative mechanism of action for OAB treatment, as it is a beta-3 adrenergic agonist. Many existing OAB treatments are anticholinergic medications, which can have side effects such as dry mouth, constipation, and cognitive impairment. Vibegron has been shown to be effective with a different side effect profile [2].
What are the side effects of Vibegron?
Common side effects reported for vibegron include headache, nasopharyngitis (common cold symptoms), and diarrhea [1].
How long does Vibegron take to work?
Patients may start to see improvements in their OAB symptoms after initiating treatment with vibegron [3].
Can men take Vibegron?
Currently, vibegron (Gemtesa) is approved in Canada only for adult women with overactive bladder [1].
What is the patent status of Vibegron?
Information regarding the specific patent status and expiry dates for Vibegron in Canada can be found through resources like DrugPatentWatch.com [4]. Patent protection is crucial for pharmaceutical companies as it grants them exclusive rights to market a drug for a certain period, influencing the availability of generic alternatives.